Albemarle Hits New 52-Week High: What's Driving the Stock?

Shares of premier specialty chemical company, Albemarle CorporationALB , scaled a new 52-week high of $114.29 yesterday, before pulling back to close the day at $113.60.

Albemarle is a leading producer of highly-engineered specialty chemicals that has a market capitalization of roughly $12.5 billion. The average volume of shares traded by the company in the past three months is 981,437.

Let's find out what are the driving factors behind this latest rally.

Strong Q1 Performance

Albemarle recorded adjusted earnings of $1.05 per share in the first quarter of 2017, topping the Zacks Consensus Estimate of 95 cents.

Revenues were $722.1 million in the first quarter, which beat the Zacks Consensus Estimate of $678.7 million.

Revenues in the first quarter rose on the back of favorable impact of higher sales volume in three reportable segments, more than offsetting the impact of divestitures of specialty chemicals business, minerals-based flame retardants and currency exchange.

Price Performance

The shares of Albemarle have been performing well of late. The company has significantly outperformed the Zacks categorized Chemicals-Diversified industry over the past three months, partly reflecting its better than expected first quarter performance and its strategic growth initiatives.

Albemarle's shares have gained around 8.2% over this period, as against the roughly 0.1% loss recorded by the industry.

Earnings Surprise

Albemarle has an impressive earnings surprise history, outpacing the Zacks Consensus Estimate in all the trailing four quarters, delivering a positive average earnings surprise of around 9%.

Rising Estimates

The current quarter estimates for Albemarle have been going up lately. The stock has witnessed seven upward and one downward estimate revisions in the past one month. This positive outlook helped to lift current quarter earnings estimate by 5.8% to $1.09 per share.

Strong Growth Prospects

Albemarle remains focused on strengthening its lithium business and is well placed to leverage strong expected growth in the battery-grade lithium market. The company's Talison joint venture in Australia has approved the expansion of lithium concentrate production at its Greenbushes mine. The expansion will double the lithium carbonate equivalent capacity at Greenbushes from 80,000 metric tons per year to more than 160,000 metric tons.

Cost-Cutting Actions

Albemarle is also selling non-core businesses and assets to boost growth opportunities and focus on its key businesses. As part of this move, the company has sold its Chemetall Surface Treatment unit to German chemical giant BASF BASFY for around $3.2 billion. Albemarle also completed the divestiture of the tribotecc metal sulfides business to Treibacher Industrie AG, as a strategic plan to focus on its core bromine, lithium, catalysts and surface treatment businesses.


The acquisition of the lithium assets of Jiangxi Jiangli New Materials Science and Technology Co. Ltd. has allowed Albemarle to supply premium lithium salts to an expanded global customer base and to reach closer to its goal of capturing 50% growth in this industry.


Albemarle in its first-quarter call revealed that it is optimistic about 2017 owing to a strong start in Lithium and Bromine Specialties. Concurrently, the company issued a favorable outlook for both businesses. The company raised sales and earnings outlook for 2017. It now expects net sales in the band of $2.9-$3.05 billion (up from $2.8-$2.95 billion expected earlier) and adjusted earnings per share of between $4.20 and $4.40 (up from $4.00-$4.25 per share) for 2017.

Albemarle Corporation Price and Consensus

Albemarle Corporation Price and Consensus | Albemarle Corporation Quote

Zacks Rank & Key Picks

Albemarle currently carries a Zacks Rank #3 (Hold).

Some top ranked companies in the chemical space include The Chemours Company CC and Kronos Worldwide, Inc. KRO , both sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here .

Chemours has expected long-term growth rate of 15.5%.

Kronos has expected long-term growth rate of 5%.

Will You Make a Fortune on the Shift to Electric Cars?

Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.

With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.

It's not the one you think.

See This Ticker Free >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

BASF SE (BASFY): Free Stock Analysis Report

Albemarle Corporation (ALB): Free Stock Analysis Report

Kronos Worldwide Inc (KRO): Free Stock Analysis Report

Chemours Company (The) (CC): Free Stock Analysis Report

To read this article on click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story


Other Topics


Latest Markets Videos


Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at

Learn More